MétaCan
Menu
Back to cohort
Record W3055458153 · doi:10.1186/s12885-020-07252-y

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

2020· article· en· W3055458153 on OpenAlexfundno aff
Suzanna J. Schraa, Karlijn L. van Rooijen, Dave E. W. van der Kruijssen, Jillian Phallen, Mark Sausen, John K. Simmons, Veerle M.H. Coupé, Wilhelmina M. U. van Grevenstein, Sjoerd G. Elias, Helena M. Verkooijen, Miangela M. Laclé, Linda J.W. Bosch, Daan van den Broek, Gerrit A. Meijer, Victor E. Velculescu, Remond J.A. Fijneman, Geraldine R. Vink, Miriam Koopman, Mich S. Dunker, Martijn F. Lutke Holzik, Ronald Hoekstra, Dirkje W. Sommeijer, Jarmila D.W. van der Bilt, Esther C. J. Consten, Geert A. Cirkel, Thijs A. Burghgraef, Emma M. van der Schans, Peter Nieboer, Ron C. Rietbroek, Jan Willem T. Dekker, Arie J. Verschoor, Koen Talsma, Rebecca P. M. Brosens, Helgi H. Helgason, Andreas Marinelli, Ignace H. J. T. de Hingh, Corina N.A.M. Oldenhuis, Jan B.�M.�J. Jansen, Henk K. van Halteren, Hein B.A.C. Stockmann, Aart Beeker, Koop Bosscha, Hans Pruijt, Leontine E.A.M.M. Spierings, Liselot Valkenburg‐van Iersel, Wouter J. Vles, Felix E. de Jongh, Hester van Cruijsen, Joost T. Heikens, D. D. E. Zimmerman, R J van Alphen, A. H. W. Schiphorst, Lobke L. van Leeuwen-Snoeks, Jeroen Vogelaar, Natascha A. J. B. Peters

Bibliographic record

VenueBMC Cancer · 2020
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsnot available
FundersStand Up To CancerNational Cancer InstituteNational Institutes of HealthMaag Lever Darm StichtingZonMwHealth~HollandMark Foundation For Cancer ResearchDr. Miriam and Sheldon G. Adelson Medical Research FoundationNewfoundland and LabradorCommonwealth Foundation
KeywordsMedicineColorectal cancerInternal medicineOxaliplatinOncologyCapecitabineCohortClinical trialClinical endpointSurgical oncologyStage (stratigraphy)CancerProspective cohort studyRandomized controlled trialSurgery

Abstract

fetched live from OpenAlex

BACKGROUND: Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form adjuvant chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicative for MRD and has high predictive value for recurrent disease. The MEDOCC-CrEATE trial investigates how many stage II CC patients with detectable ctDNA after surgery will accept ACT and whether ACT reduces the risk of recurrence in these patients. METHODS/DESIGN: MEDOCC-CrEATE follows the 'trial within cohorts' (TwiCs) design. Patients with colorectal cancer (CRC) are included in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) and give informed consent for collection of clinical data, tissue and blood samples, and consent for future randomization. MEDOCC-CrEATE is a subcohort within PLCRC consisting of 1320 stage II CC patients without indication for ACT according to current guidelines, who are randomized 1:1 into an experimental and a control arm. In the experimental arm, post-surgery blood samples and tissue are analyzed for tissue-informed detection of plasma ctDNA, using the PGDx elio™ platform. Patients with detectable ctDNA will be offered ACT consisting of 8 cycles of capecitabine plus oxaliplatin while patients without detectable ctDNA and patients in the control group will standard follow-up according to guideline. The primary endpoint is the proportion of patients receiving ACT when ctDNA is detectable after resection. The main secondary outcome is 2-year recurrence rate (RR), but also includes 5-year RR, disease free survival, overall survival, time to recurrence, quality of life and cost-effectiveness. Data will be analyzed by intention to treat. DISCUSSION: The MEDOCC-CrEATE trial will provide insight into the willingness of stage II CC patients to be treated with ACT guided by ctDNA biomarker testing and whether ACT will prevent recurrences in a high-risk population. Use of the TwiCs design provides the opportunity to randomize patients before ctDNA measurement, avoiding ethical dilemmas of ctDNA status disclosure in the control group. TRIAL REGISTRATION: Netherlands Trial Register: NL6281/NTR6455 . Registered 18 May 2017, https://www.trialregister.nl/trial/6281.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.033
metaresearch head score (Gemma)0.031
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.054
Threshold uncertainty score0.179

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0330.031
Meta-epidemiology (narrow)0.0050.003
Meta-epidemiology (broad)0.0070.004
Bibliometrics0.0010.002
Science and technology studies0.0030.003
Scholarly communication0.0040.003
Open science0.0030.002
Research integrity0.0060.007
Insufficient payload (model declined to judge)0.0540.014

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.057
GPT teacher head0.379
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations59
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueBMC CancerSame topicCancer Genomics and DiagnosticsFrench-language works237,207